STAT+: ARPA-H funds biotechs working on custom RNA therapies

STAT PlusNewsletterThe Readout ARPA-H funds biotechs working on custom RNA therapies Roche licenses a tri-specific antibody, new Trump deals may undercut its own goals, and other biotech news Manage alerts for this article Email this article Share this article By Elaine ChenSept. 2, 2026 National Biotech Reporter Elaine Chen[email protected]Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.

You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. I was extremely confused when I saw a Spirit Halloween pop-up yesterday, but then realized October is indeed next month. Very spooky.Advertisement The need-to-know this morning UniQure submitted applications to the FDA and the UK’s MHRA, seeking the marketing approval of AMT-130, its treatment for Huntington’s disease.

New Trump deals may undercut efforts to lower costs The midterms are fast approaching, and President Trump hailed the new deals he struck with biopharma companies this week as part of his commitment to lowering drug costs. But in reality, the agreements may not amount to much, STAT’s John Wilkerson writes — and could even undercut the administration’s own efforts. STAT+ Exclusive Story Already have an account?

Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%!

Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Elaine Chen National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector.

She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Politics September 1, 2026 STAT Plus: 5 burning questions on Trump’s latest deals with drugmakers The Readout September 1, 2026 STAT Plus: Novartis gets multiple sclerosis win with BTK inhibitor Advertisement D.C.

Diagnosis September 1, 2026 STAT Plus: Will House delay Trump plan to politicize NIH grants? Pharma August 31, 2026 STAT Plus: Trump strikes nine more deals with drugmakers to lower prices The Readout August 31, 2026 STAT Plus: Can a pregnancy hormone steer a cardiovascular treatment? Subscriber Picks